| Symbol | PGEN |
|---|---|
| Name | PRECIGEN, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, Maryland, 20876, United States |
| Telephone | +1 301 556-9900 |
| Fax | — |
| — | |
| Website | http://www.precigen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001356090 |
| Description | Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexons business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The companys collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. Additional info from NASDAQ: |
Thomasian Harry Jr. 🔴 sold 200.0K shares of PRECIGEN, INC. (PGEN) at $5.78 ($1.1M) Transaction Date: Jun 29, 2026 | Filing ID: 009980
Read moreShah Rutul R 🟡 adjusted position in 42.9K shares (1 derivative) of PRECIGEN, INC. (PGEN) at $5.85 Transaction Date: Jun 29, 2026 | Filing ID: 009979
Read moreSabzevari Helen 🟡 adjusted position in 346.8K shares (1 derivative) of PRECIGEN, INC. (PGEN) at $5.89 ($3.7M) Transaction Date: Jun 29, 2026 | Filing ID: 009978
Read more📋 Thomasian Harry Jr. (Officer) plans to sell 171K shares of PRECIGEN, INC. (at $5.53 each, total $949K) Filed: Jul 01, 2026 | ID: 005006
Read more📋 Sabzevari Helen (Officer) plans to sell 347K shares of PRECIGEN, INC. (at $5.90 each, total $2.0M) Filed: Jun 29, 2026 | ID: 004954
Read more📋 Shah Rutul R (Officer) plans to sell 43K shares of PRECIGEN, INC. (at $5.85 each, total $251K) Filed: Jun 29, 2026 | ID: 004941
Read more📋 Thomasian Harry Jr. (Officer) plans to sell 29K shares of PRECIGEN, INC. (at $5.78 each, total $165K) Filed: Jun 29, 2026 | ID: 004937
Read morePrecigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Read moreThomasian Harry Jr. 🔴 sold 41.9K shares of PRECIGEN, INC. (PGEN) at $4.36 Transaction Date: May 28, 2026 | Filing ID: 008173
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metas… | Phase2 | Cervical Cancer | Recruiting | 2025-11-11 | 2030-11-30 | ClinicalTrials.gov |
| NCT06538480 | Zopa Retreatment and Vector Shedding in Adults With RRP | Phase4 | Recurrent Respiratory Papillomatosis | Recruiting | 2024-07-11 | 2028-12-02 | ClinicalTrials.gov |
| NCT05694364 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients … | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2023-01-25 | 2024-04-18 | ClinicalTrials.gov |
| NCT04724980 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | Phase1 | Recurrent Respiratory Papillomatosis | Active_Not_Recruiting | 2021-03-16 | 2026-06-05 | ClinicalTrials.gov |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AM… | Phase1 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2019-05-20 | 2025-08-01 | ClinicalTrials.gov |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanc… | Phase1 | Platinum-Resistant Fallopian Tube Carcinoma | Active_Not_Recruiting | 2019-04-30 | 2028-11-15 | ClinicalTrials.gov |
| NCT03751007 | A Study to Assess the Safety and Tolerability of Different Doses of AG019 Admin… | Phase1 | Diabetes type1 | Completed | 2018-10-24 | 2021-10-13 | ClinicalTrials.gov |
| NCT03409627 | Novel INXN-4001 Triple Effector Plasmid in Heart Failure | Phase1 | Heart Failure | Completed | 2018-04-09 | 2020-08-12 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PRGN-3005 UltraCAR-T cells | Other | Phase PHASE1 | Platinum-Resistant Fallopian Tube Carcinoma | ACTIVE_NOT_RECRUITING | NCT03907527 |
| INXN-4001 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT03409627 |
| AG019 - High Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-AG019 | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| AG019 - Low Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| AG019 - High Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Placebo-AG019 | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| Teplizumab | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| AG019 - Low Dose | Other | Phase PHASE1 | Diabetes type1 | COMPLETED | NCT03751007 |
| PRGN-3006 T Cells | Other | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03927261 |
| PRGN-2012 - Phase II; Dose Level 2 | Other | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 2 | Other | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 1 | Other | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-3007 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Cyclophosphamide | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Fludarabine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| Zopapogene imadenovec (Zopa) | Other | Phase PHASE4 | Recurrent Respiratory Papillomatosis | RECRUITING | NCT06538480 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| Zopapogene imadenovec (Zopa) | DRUG | Phase PHASE4 | Recurrent Respiratory Papillomatosis | RECRUITING | NCT06538480 |
| Pembrolizumab alone | DRUG | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-2009 plus Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT06157151 |
| PRGN-3007 | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| Fludarabine | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT05694364 |
| PRGN-2012 - Phase II; Dose Level 2 | DRUG | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 2 | DRUG | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-2012 - Phase I; Dose Level 1 | DRUG | Phase PHASE1 | Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | NCT04724980 |
| PRGN-3006 T Cells | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03927261 |
| PRGN-3005 UltraCAR-T cells | BIOLOGICAL | Phase PHASE1 | Platinum-Resistant Fallopian Tube Carcinoma | ACTIVE_NOT_RECRUITING | NCT03907527 |
| INXN-4001 | BIOLOGICAL | Phase PHASE1 | Heart Failure | COMPLETED | NCT03409627 |